Alexion Pharmaceuticals, Inc.

Quick facts

Marketed products

• Ultomiris · Other

Phase 3 pipeline

• ALXN1850 · Nephrology / Immunology
  ALXN1850 is a proximal tubule-targeted complement C3 inhibitor that reduces complement-mediated kidney damage in rare kidney diseases.
• ALXN2060 · Immunology / Hematology
  ALXN2060 is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage.
• C5 Inhibitor · Immunology
  A C5 complement inhibitor blocks the activation of the C5 component of the complement cascade, preventing formation of the membrane attack complex and reducing inflammatory cell activation.
• CAEL-101 · Rare Disease / Amyloidosis
  CAEL-101 is a transthyretin (TTR) stabilizer that binds to and stabilizes the transthyretin protein, preventing its misfolding and amyloid fibril formation.
• pexelizumab in conjunction with CABG · Cardiovascular
  Pexelizumab is a monoclonal antibody that inhibits the complement component 5 (C5) to reduce inflammation.

Phase 2 pipeline

• ACH-0144471 · Autoimmune diseases
  ACH-0144471 is a monoclonal antibody targeting the CD40 receptor.
• ACH-126,443
• ALXN1920
• ALXN2030 · Genetics and Rare Diseases
  ALXN2030 is a recombinant human alpha-L-iduronidase enzyme replacement therapy.
• ALXN2420
• Bis-Choline Tetrathiomolybdate · Neurology
  Bis-Choline Tetrathiomolybdate is a chelating agent that binds to copper, reducing its availability for incorporation into ceruloplasmin and subsequent deposition in the brain.
• hLB-001
• Retrospective Case Only

Phase 1 pipeline

• [14C]-ALXN2050
• [14C]-Danicopan
• ACH-0143102
• ACH-0145228
• ACH-0145228: Immediate Release
• ACH-0145228: Powder-in-capsule
• ALXN1007
• ALXN1210 · Rare Disease
  Complement inhibitor
• ALXN1210 IV · Rare Disease
  ALXN1210 is a C5 complement inhibitor that blocks the terminal complement cascade.
• ALXN1210 SC
• ALXN1720
• ALXN1720 IV
• ALXN1720 SC
• ALXN1820 IV
• ALXN1820 SC
• ALXN1840 Enteric-coated Tablet
• ALXN1840 Non-coated Capsule
• ALXN1910
• ALXN2040
• ALXN2050 MR Prototype Mini-Tablet
• ALXN2050 MR Prototype Tablet
• ALXN2080
• ALXN2230
• ALXN2350
• AZP-3601
• Danicopan - LFC
• Danicopan Modified Release Prototype 1
• Danicopan Modified Release Prototype 2
• Danicopan Modified Release Prototype 3
• Danicopan: Powder-In-Capsule 1
• Danicopan: Powder-In-Capsule 2
• Danicopan - Softgel
• Danicopan - Tablet
• Gefurulimab AI
• Gefurulimab PFS-SD

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Alexion Pharmaceuticals, Inc. portfolio CI brief
• Alexion Pharmaceuticals, Inc. pipeline updates RSS